Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

ASN 002 - Ascend Biopharmaceuticals

Next Previous
Search
Drug Profile

ASN 002 - Ascend Biopharmaceuticals

Alternative Names: Ad-IFNγ; Adenovirus interferon gamma; ASN-002 - Ascend; SP-002 - Stamford Pharmaceuticals; SP-105 - Stamford Pharmaceuticals; TG-1042

Latest Information Update: 13 Sep 2024

Price :
$50 *
Note:
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator Transgene
  • Developer Ascend Biopharmaceuticals; Nantes University Hospital; Transgene
  • Class Antineoplastics; Cancer vaccines; Immunotherapies; Synthetic vaccines
  • Mechanism of Action Immunostimulants
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    Yes - Basal cell nevus syndrome; Cutaneous T-cell lymphoma
  • New Molecular Entity No

Highest Development Phases

  • Phase II Basal cell cancer
  • Preclinical Cancer
  • No development reported Malignant melanoma
  • Discontinued Cutaneous B-cell lymphoma; Cutaneous T-cell lymphoma

Most Recent Events

  • 13 Sep 2024 Preclinical trials in Cancer in USA (unspecified route) (Stamford pharmaceuticals pipeline; September 2024)
  • 13 Sep 2024 Stamford Pharmaceuticals plans phase-I/IIa trial for Squamous cell cancer (Combination therapy) in H1 2025 (Stamford pharmaceuticals pipeline; September 2024)
  • 09 Apr 2024 Phase-II clinical trials in Basal cell cancer (Combination therapy, Late-stage disease) in USA (Intratumoural) (NCT06344052)

You need to be a logged in or subscribed to view this content Request demo (opens in a new window)

If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top